Occurrence of Fatal and Nonfatal Adverse Outcomes after Heart Transplantation in Patients with Pretransplant Noncytotoxic HLA Antibodies
Figure 2
Kaplan-Meier estimate survival in patients with HLA ab. (a) Overall survival in patients with (solid line) and without (dotted line) pretransplant HLA ab. Vertical lines indicate standard errors of the survival estimate. (b) Overall survival according with HLA antibodies against either class I or II alone (dotted line), both class I and II (solid line), or no HLA antibodies. Vertical lines indicate standard errors of the survival estimate.
